The United Nations Office at Geneva
Multimedia Newsroom
COVID-19: UN health agency issues conditional advice against using remdesivir
Patients with COVID-19 should not be given the antiviral drug remdesivir “regardless of disease severity”, the UN World Health Organization (WHO) said on Friday.
Nonetheless, describing its recommendation as “conditional”, as opposed to “strong”, WHO stressed that data from a global trial on the efficacy of remdesivir was inconclusive, and that further trials should continue into its use for more vulnerable patients.
“We recommend a conditional recommendation – I want to highlight that - against the use of remdesivir in hospitalised patients with COVID-19 regardless of disease severity,” said Dr Janet Diaz, Head of Clinical Care at WHO, during a virtual press conference in Geneva.
According to data from the WHO-led Solidarity trial which was then examined by a panel of international experts behind the recommendation, “possibly remdesivir can lead to 29 fewer deaths per 1,000 patients or up to 11 more deaths per 1000 patients”, Dr Diaz said. “So you can see that …the confidence interval are relatively large…there was no evidence that there was any important effect on mortality, on the need for mechanical ventilation or the time to clinical improvement.”
But this did “not prove” that the antiviral “had no benefit at all”, Dr Diaz insisted. “There could still be potential small benefit, maybe in a health sub-group which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
The WHO official explained that this might be “severe patients versus critical patients” or whether the antiviral is used “early versus late”.
Dr Bram Rochwerg, who was among the experts advising WHO, noted that there would likely be regional “variations” in the use of remdesivir.
While a minority of people will still choose to use it, the majority would not, based on the available data, he said.
“There may be groups (who might benefit) and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit,” he said. “We were very explicit that we do believe that these studies need to continue (and) Solidarity is continuing.”
Although the remdesivir development mirrors similar attempts to use other antivirals against the new coronavirus, Dr Diaz said there was no reason to lose hope in the fight against COVID-19.
“I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
Latest data from WHO indicates that eight in 10 people infected with COVID report mild symptoms, Dr Diaz said.
“Since the beginning (of the pandemic)…about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
Nonetheless, there are reports of more “persistent longer-term symptoms”, Dr Diaz noted. “So even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We recommend a conditional recommendation - so I want to highlight that, it’s a conditional recommendation - against the use of remdesivir in hospitalized patients - with COVID-19, regardless of disease severity.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Possibly remdesivir can lead to 29 fewer deaths par 1,000 patients or up to 11 more deaths per 1,000 patients so you can see that this is, the confidence interval is a little bit large.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “It was not clear that, there was no evidence, that there was any important effect on mortality, on the need for mechanic ventilation or the time to clinical improvement.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “This did not prove that remdesivir does not have a benefit at all and that’s why it is a conditional recommendation, there can still be potential small benefit, maybe in a health sub-group, which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “You know, is there a sub-group that may benefit more – such as severe patients versus critical patients. Is there a timing in disease that may benefit more - such as early versus late - and those are all considerations that are in the guidelines.”
- SOUNDBITE (English) — Dr Bram Rochwerg, practising ITU clinician and expert adviser for WHO-led Solidarity Trial: “There may be groups and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit. And as she said, we were very explicit that we do believe that these studies need to continue, Solidarity is continuing, so.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to, I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Since the beginning, is that about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We do know that even patients with mild disease may have persistent longer-term symptoms. And that has been now described; so even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”
Similar Stories
1
1
1
Edited News | UN WOMEN
In war-torn Gaza, a growing number of women-headed households face “impossible decisions” every day, amid ongoing Israeli airstrikes and still-scarce resources, UN humanitarians said on Tuesday.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk made the following remarks to the Enhanced Interactive Dialogue on the Independent Investigative Mechanism for Myanmar at the 63rd Human Rights Council.
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk today delivered an update on the global human rights situation to the 63rdsession of the Human Rights Council in Geneva.
1
1
1
Edited News | WHO
Repeated attacks on humanitarian warehouses put vital medical aid at risk in Ukraine - WHO
A new airstrike overnight damaged one of the main warehouses used by the UN health agency to store humanitarian medical supplies in the Kyiv region, the World Health Organization (WHO) said on Friday. This is the third attack to affect a WHO-used storage in the last three months.
2
2
2
Press Conferences , Edited News | WMO
Powerful El Niño heightens extreme-weather risks through 2027, as countries brace for impact - WMO
Fuelled by extraordinarily warm waters across the tropical Pacific Ocean, the El Niño climate pattern is expected to intensify in the coming months. Forecasters are almost certain that it will persist through February next year, with unusually warm conditions expected across the globe.
1
1
1
Edited News | OCHA , IFRC , UN WOMEN , WHO
Nepal flood deaths near 1,000 as those spared struggle to survive – UN humanitarians
With the death toll in Nepal’s catastrophic flash floods inching towards 1,000, rescue workers are facing harsh conditions while survivors lack access to food, safe water and health care, humanitarians said on Tuesday.
1
1
1
Edited News | OCHA , UNDRR , IFRC , WHO
Nepal: Flooding disaster “not over” as humanitarians work around the clock
While search and rescue efforts continued Friday following flash floods and mudslides in northern Nepal, UN humanitarians are taking stock of the devastation amid concerns over more flooding to come.
1
1
1
Edited News | UNIFIL
Damaged roads, disrupted services and renewed military activity are putting civilians at risk in south Lebanon, UN Interim Force in Lebanon (UNIFIL) warns.
The UN peacekeeping mission is urging restraint and renewed political engagement to prevent further escalation.
1
1
1
Edited News | ICRC , UNODA
Amid unconfirmed reports that fully autonomous and AI-guided drones are now being used on the battlefield, UN chief António Guterres and the President of the Red Cross on Tuesday renewed their urgent call for stricter controls, before it is too late.
1
1
1
Edited News | UNICEF
Somalia: child hunger surges as humanitarian aid dries up – UNICEF
The global funding crisis for vital lifesaving work is taking a growing toll on the most vulnerable children in Somalia, where hundreds of health and nutrition facilities have been forced to close, the UN Children’s Fund (UNICEF) warned on Friday
1
1
1
Edited News | OCHA
As the deadliest Ebola outbreak in DR Congo’s history continued spreading on Friday, UN responders renewed their urgent appeal for immediate international support, with existing funding for lifesaving work critically low.
1
1
1
Edited News | WHO
DRC: In the fight against Ebola, bikers transporting dead bodies hold key to community engagement - WHO
From the frontlines of the deadliest-ever Ebola Bundibugyo outbreak in the Democratic Republic of the Congo (DRC), the UN’s World Health Organization (WHO) shared details on Tuesday of a massive push for community engagement, a day after yet another ambulance attack.